- August 24, 2022
On June 23, 2022, the FDA unveiled its Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS) – a five-year strategy for improving and extending the lives of people living with rare neurodegenerative diseases by advancing the development of safe and effective medical products and facilitating patient access to novel treatments.
We'd like to cordially invite you to a virtual stakeholder webinar on August 24, 2022, from 3:00 p.m. to 4:00 p.m. ET, to hear from NIH and FDA subject matter experts about the ACT for ALS.
- Welcome and Overview of the ACT for ALS
- FDA Rare Neurodegenerative Disease Grant Program
- FDA Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis
- NIH/NINDS Grant Program for Research Utilizing Data from Expanded Access
- Questions and Answers